Fall 2009

The President of the National Pharmaceutical Council discusses how comparative effectiveness research and value-based insurance design can reduce costs and improve healthcare quality.

This retrospective study of 558.9 million prescription claims explores how member age demographics affect prescription drug trends and provides top therapeutic classes by generation.

Focusing first on patient needs is the key to finding a meaningful and effective solution to the complex issues regarding regulation of biosimilars.

Among patients with poor statin adherence, adequate antidepressant treatment significantly improved adherence and persistence compared with inadequate or no antidepressant treatment.

Pharmacist-administered vaccination services were found to be more efficient, productive, and cost-effective than primary care visits or mass vaccination clinics.

P&T committees should implement more rigorous formulary restrictions that stimulate manufacturers to meet a higher standard when bringing new therapies to market.

The Society seeks input from both individuals and organizations as it creates a new environment of data-driven P&T best practices.

Differences in formulary coverage of antihypertensive medications for children between private and public insurance plans may impact physician prescribing practices and patient outcomes.

The authors advocate pharmacoeconomic evaluation of new antihypertensive drugs before acceptance by formulary decision makers.